PTPN11 and leukemia: Recent data suggest that disruptions of the protein–protein interaction (PPI) interface of the SHP2 SH2 domain, rather than its enzymatic activity, may be a more effective approach to inhibiting SHP2 biological activity in the setting of mutations that are linked to childhood myelodysplastic syndromes and various forms of leukemias.